Barclays’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Barclays’s Portfolio NBP Stock Details NBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$544K	Sell	279,019 -20,280	-7%	-$41.4K	﹤0.01%	3164
2026 Q1	$736K	Sell	299,299 -329,624	-52%	-$1.1M	﹤0.01%	2945
2025 Q4	$2.5M	Buy	628,923 +233,492	+59%	+$1.03M	﹤0.01%	2775
2025 Q3	$1.49M	Buy	395,431 +365,061	+1,202%	+$1.24M	﹤0.01%	3104
2025 Q2	$73.5K	Hold	30,370	–	–	﹤0.01%	4644
2025 Q1	$25K	Hold	30,370	–	–	﹤0.01%	4754
2024 Q4	$25.8K	Hold	30,370	–	–	﹤0.01%	4883
2024 Q3	$37.7K	Hold	30,370	–	–	﹤0.01%	4804
2024 Q2	$50.7K	Sell	30,370 -8,182	-21%	-$14.6K	﹤0.01%	4209
2024 Q1	$71.7K	Sell	38,552 -134,512	-78%	-$248K	﹤0.01%	4538
2023 Q4	$329K	Buy	173,064 +60,597	+54%	+$90.5K	﹤0.01%	4150
2023 Q3	$148K	Hold	112,467	–	–	﹤0.01%	3426
2023 Q2	$336K	Sell	112,467 -317,939	-74%	-$1.02M	﹤0.01%	2988
2023 Q1	$1.49M	Buy	430,406 +101,106	+31%	+$490K	﹤0.01%	2427
2022 Q4	$1.38M	Buy	+329,300	New	+$1.25M	﹤0.01%	2546
2022 Q2	–	Sell	-240,881	Closed	-$3.91M	–	5139
2022 Q1	$3.91M	Buy	+240,881	New	+$6.17M	﹤0.01%	1379

Other funds holding NBP

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACM

AIHC Capital Management Central $104M AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's NBP Position: Q2 2026 in Review

Barclays reduced its NovaBridge Biosciences American Depositary Shares (NBP) stake by 6.8% in Q2 2026, selling an estimated $41.4K and leaving 279,019 shares worth $544K. The position accounts for ﹤0.01% of the portfolio, ranked #3164.

Barclays first reported a position in NBP in Q1 2022 and has held it in 16 quarters since. The position peaked at $3.91M in Q1 2022. 49 funds tracked by Wall St. Rank hold NBP as of Q2 2026.

Barclays held 279,019 shares of NovaBridge Biosciences American Depositary Shares worth $544K as of Q2 2026.
Barclays sold 20,280 NovaBridge Biosciences American Depositary Shares shares in Q2 2026, an estimated $41.4K.
NovaBridge Biosciences American Depositary Shares made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3164 holding.
Barclays first reported a position in NovaBridge Biosciences American Depositary Shares in Q1 2022 and has held it in 16 quarters since.
Barclays's NovaBridge Biosciences American Depositary Shares position peaked at $3.91M in Q1 2022.
49 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.